Galina Statsenko

7.3k citations
23 papers · 3.2k · 4 hit papers · h-index 10

Impact in

  • Oncology top 1%
    • Lung Cancer Research Studies
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Treatments and Mutations
    • Brain Metastases and Treatment
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Lung Cancer Research Studies 11
    • Cancer Immunotherapy and Biomarkers 3
    • Renal cell carcinoma treatment 3
    • Lung Cancer Treatments and Mutations 2
    • Lung Cancer Diagnosis and Treatment 2
    • Gastric Cancer Management and Outcomes 2

Galina Statsenko

22 papers receiving 3.1k citations

Galina Statsenko's Hit Papers

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN 2022 · 242 citations
2420+2+4Years since publication5001k1.5k

Peers

Galina Statsenko
Comparison fields: 5 of 60
  • Oncology 2.4k
  • Pulmonary and Respiratory Medicine 373
  • Surgery 309
  • Epidemiology 93
  • Cancer Research 37
Replace Eric Scott Schaefer with:
Eric Scott Schaefer United States
Marta López Brea Spain
Sivuonthanh Lam United States
Y. Ostapenko Ukraine
Ji‐Feng Feng China
Ahmet DEMİRKAZIK Türkiye
Margarita Majem Tarruella Spain
Veronika Sárosi Hungary
Mauro Minelli Italy
Nikolay Vladimirov Conev Bulgaria
Galina Statsenko relative to Eric Scott Schaefer United States Eric Scott Schaefer's profile →
Citations per field
00.5×1.5×
Eric Scott Schaefer · 1×
Citations per year

Countries citing papers authored by Galina Statsenko

Since Specialization
Citations

This map shows the geographic impact of Galina Statsenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Galina Statsenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Galina Statsenko more than expected).

Fields of papers citing papers by Galina Statsenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Galina Statsenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Galina Statsenko. The network helps show where Galina Statsenko may publish in the future.

Co-authors

The 25 scholars most cited alongside Galina Statsenko, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Galina Statsenko Line = papers co-authored together Galina Statsenko links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Hit paper breakdown →
20191737
2
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Hit paper breakdown →
2020522
3
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Hit paper breakdown →
2020408
4
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
Hit paper breakdown →
2022242
5 201949
6 202345
7 202039
8 202232
9 201727
10 202522
11 20199
12 20209
13 20237
14 20196
15 20214
16 20224
17 20193
18 20202
19 20221
20 20231

About Galina Statsenko

Galina Statsenko is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Economics and Econometrics and Molecular Biology, having authored 23 papers that have together received 3.2k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (11 papers), Cancer Immunotherapy and Biomarkers (3 papers), Renal cell carcinoma treatment (3 papers), Lung Cancer Treatments and Mutations (2 papers), Lung Cancer Diagnosis and Treatment (2 papers), Bladder and Urothelial Cancer Treatments (2 papers), Gastric Cancer Management and Outcomes (2 papers) and Economic and Financial Impacts of Cancer (1 paper). The work is most often cited by research in Oncology (2.4k citations), Pulmonary and Respiratory Medicine (373 citations), Surgery (309 citations), Epidemiology (93 citations) and Cancer Research (37 citations). Galina Statsenko has collaborated with scholars based in Russia, United States and United Kingdom. Frequent co-authors include Maximilian Johannes Hochmair, Niels Reinmuth, Jonathan Wade Goldman, Mustafa Özgüroğlu, Marina Chiara Garassino, Luis G Paz-Ares, Jun Ho Ji, Katsuyuki Hotta, Libor Havel and Haiyi Jiang. Their work appears in journals such as Annals of Oncology, The Lancet Oncology, The Lancet, Lung Cancer and Clinical Genitourinary Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact